Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05802173Phase 2Completed

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Role: lead

NCT06363461Phase 2Completed

Study of TDM-180935 in Atopic Dermatitis Patients

Role: lead

NCT05525468Phase 1Completed

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

Role: lead

NCT05244980Phase 1Completed

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Role: lead

NCT04913519Phase 1Completed

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

Role: lead

All 5 trials loaded